BriaCell Overall Survival Data Selected for Spotlight Poster at 2024 San Antonio Breast Cancer Symposium®, December 10 – 13
BriaCell Therapeutics (Nasdaq: BCTX) announces five poster presentations, including a Spotlight poster, at the 2024 San Antonio Breast Cancer Symposium®. The presentations will showcase updated survival data and key biomarker findings from their Phase 2 trial of Bria-IMT™ plus immune checkpoint inhibitor in metastatic breast cancer. The presentations will also detail their planned Phase 3 study design for expanding Bria-IMT™ + CPI treatment to cancer patients with central nervous system metastases. The symposium will be held December 10-13, 2024, in San Antonio, Texas.
BriaCell Therapeutics (Nasdaq: BCTX) annuncia cinque presentazioni di poster, compreso un poster Spotlight, al 2024 San Antonio Breast Cancer Symposium®. Le presentazioni metteranno in evidenza i dati aggiornati sulla sopravvivenza e i principali risultati sui biomarcatori del loro studio di Fase 2 di Bria-IMT™ in combinazione con inibitori dei checkpoint immunitari nel cancro al seno metastatico. Le presentazioni dettaglieranno anche il design dello studio di Fase 3 pianificato per ampliare il trattamento con Bria-IMT™ + CPI a pazienti affetti da cancro con metastasi al sistema nervoso centrale. Il simposio si terrà dal 10 al 13 dicembre 2024 a San Antonio, Texas.
BriaCell Therapeutics (Nasdaq: BCTX) anuncia cinco presentaciones de carteles, incluyendo un cartel Spotlight, en el 2024 San Antonio Breast Cancer Symposium®. Las presentaciones mostrarán datos actualizados sobre la supervivencia y hallazgos clave de biomarcadores de su ensayo de Fase 2 de Bria-IMT™ más un inhibidor de puntos de control inmune en cáncer de mama metastásico. Las presentaciones también detallarán el diseño de su estudio de Fase 3 previsto para ampliar el tratamiento de Bria-IMT™ + CPI a pacientes con metástasis en el sistema nervioso central. El simposio se llevará a cabo del 10 al 13 de diciembre de 2024 en San Antonio, Texas.
BriaCell Therapeutics (Nasdaq: BCTX)는 2024 샌안토니오 유방암 심포지엄®에서 스포트라이트 포스터를 포함한 다섯 개의 포스터 발표를 발표합니다. 발표에서는 전이성 유방암에서 Bria-IMT™와 면역 체크포인트 억제제를 포함한 2상 시험에서의 업데이트된 생존 데이터와 주요 바이오마커 결과를 선보일 것입니다. 또한, 발표에서는 중추신경계 전이 환자에게 Bria-IMT™ + CPI 치료를 확장하기 위해 계획된 3상 연구 디자인을 상세하게 설명할 것입니다. 이 심포지엄은 2024년 12월 10일부터 13일까지 텍사스 주 샌안토니오에서 개최됩니다.
BriaCell Therapeutics (Nasdaq: BCTX) annonce cinq présentations d'affiches, y compris une affiche Spotlight, lors du 2024 San Antonio Breast Cancer Symposium®. Les présentations mettront en avant des données actualisées sur la survie et des résultats clés de biomarqueurs de leur essai de Phase 2 de Bria-IMT™ en association avec un inhibiteur de point de contrôle immunitaire dans le cancer du sein métastatique. Les présentations détailleront également leur conception d'étude de Phase 3 prévue pour étendre le traitement Bria-IMT™ + CPI aux patients atteints de métastases du système nerveux central. Le symposium se tiendra du 10 au 13 décembre 2024 à San Antonio, Texas.
BriaCell Therapeutics (Nasdaq: BCTX) gibt fünf Posterpräsentationen bekannt, darunter ein Spotlight-Poster, auf dem 2024 San Antonio Breast Cancer Symposium®. Die Präsentationen werden aktualisierte Überlebensdaten und wichtige Biomarkerkampagnien aus ihrer Phase-2-Studie zu Bria-IMT™ plus Immun-Checkpoint-Inhibitoren bei metastasierendem Brustkrebs präsentieren. Die Präsentationen werden auch das geplante Studiendesign der Phase 3 detaillieren, um die Behandlung mit Bria-IMT™ + CPI bei Krebspatienten mit Metastasen im zentralen Nervensystem zu erweitern. Das Symposium findet vom 10. bis 13. Dezember 2024 in San Antonio, Texas, statt.
- Selected for Spotlight Poster presentation at major breast cancer symposium, indicating significant scientific recognition
- Phase 3 study expansion planned to include broader patient population with CNS metastases
- Multiple presentations (5) accepted at prestigious conference, demonstrating strong research pipeline
- None.
Insights
The upcoming presentation at SABCS focuses on clinical trial data for Bria-IMT™, BriaCell's immunotherapy treatment, but lacks immediate actionable results. While the spotlight poster on overall survival data suggests potentially significant findings, the actual data and implications remain undisclosed until the December conference.
The five poster presentations cover important aspects including:
- Overall survival results
- Biomarker identification
- PD-L1 expression analysis
- CNS metastases treatment potential
- Tumor microenvironment effects
However, without the actual data being presented, this announcement represents a standard conference preview rather than market-moving news. The Phase 3 study expansion to CNS metastases patients indicates promising development direction but requires actual trial results to assess impact.
- Five BriaCell poster presentations to highlight updated survival and key biomarker data from Phase 2 trial of Bria-IMT™ plus immune check point inhibitor in metastatic breast cancer
- Presentations include planned Phase 3 study design expanding use of Bria-IMT™ + CPI to any cancer patient with central nervous system (CNS) metastases
PHILADELPHIA and VANCOUVER, British Columbia, Nov. 04, 2024 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care, announces five posters, including a Spotlight poster presentation, at the San Antonio Breast Cancer Symposium® (SABCS®) 47th Annual Meeting, being held December 10 – 13 , 2024, at the Henry B. Gonzalez Convention Center, San Antonio, Texas.
“At BriaCell, we remain committed to advancing our novel therapies to improve cancer patients’ lives,” stated William V. Williams, MD, BriaCell’s President & CEO. “Having five poster presentations, including a spotlight poster, attests to the depth and breadth of our research and clinical development efforts at BriaCell. We look forward to sharing our data with scientific experts and cancer specialists seeking better clinical outcomes.”
The details about the Spotlight presentation and other poster sessions are as follows:
Abstract Number: SESS-1071 (Spotlight Poster)
Title: Overall survival results of Bria-IMT allogenic whole cell-based cancer vaccine
Time: Wednesday, December 11, 2024 7:00 AM – 8:30 AM CST
Presentation ID: PS3-06
Abstract Number: SESS-1431
Title: Identification of antigenic determinants in SV-BR-1 derived cellular breast cancer vaccines
Time: Wednesday, December 11, 2024 5:30 – 7:00 PM CST
Presentation ID: P2-06-02
Abstract Number: SESS-2217
Title: PD-L1 upregulation in circulating tumor associated cells predicts for clinical outcomes in a phase I/II clinical trial using SV-BR-1-GM vaccine with the checkpoint inhibitor retifanlimab in metastatic breast cancer patients, an interim analysis
Time: Wednesday, December 11, 2024 12:00 – 2:00 PM CST
Presentation ID: P1-01-17
Abstract Number: SESS-1068
Abstract Title: ASTRO-VAC CNS: Bria-IMT in the management of tumor agnostic metastatic CNS lesions
Time: Wednesday, December 11, 2024 5:30 – 7:00 PM CST
Presentation ID: P2-10-24
Abstract Number: SESS-1069
Title: Bria-IMT CD8+ tumor infiltrating lymphocytes turn “Cold” tumor “Hot” in metastatic breast cancer
Time: Friday, December 13, 2024 12:00 PM – 2:00 PM CST
Presentation ID: P5-10-12
Following the presentation, copies of the posters will be posted on https://briacell.com/scientific-publications/.
About BriaCell Therapeutics Corp.
BriaCell is a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care. More information is available at https://briacell.com/.
Safe Harbor
This press release contains “forward-looking statements” that are subject to substantial risks and uncertainties. All statements, other than statements of historical fact, contained in this press release are forward-looking statements. Forward-looking statements contained in this press release may be identified by the use of words such as “anticipate,” “believe,” “contemplate,” “could,” “estimate,” “expect,” “intend,” “seek,” “may,” “might,” “plan,” “potential,” “predict,” “project,” “target,” “aim,” “should,” “will,” “would,” or the negative of these words or other similar expressions, although not all forward-looking statements contain these words. Forward-looking statements, including those about BriaCell continuing to advance its novel targeted immunotherapy candidates; and BriaCell sharing data with scientific experts and cancer specialists are based on BriaCell’s current expectations and are subject to inherent uncertainties, risks, and assumptions that are difficult to predict. Further, certain forward-looking statements, such as those are based on assumptions as to future events that may not prove to be accurate. These and other risks and uncertainties are described more fully under the heading “Risks and Uncertainties” in the Company’s most recent Management’s Discussion and Analysis, under the heading “Risk Factors” in the Company’s most recent Annual Information Form, and under “Risks and Uncertainties” in the Company’s other filings with the Canadian securities regulatory authorities and the U.S. Securities and Exchange Commission, all of which are available under the Company's profiles on SEDAR+ at www.sedarplus.ca and on EDGAR at www.sec.gov. Forward-looking statements contained in this announcement are made as of this date, and BriaCell Therapeutics Corp. undertakes no duty to update such information except as required under applicable law.
Neither the Toronto Stock Exchange nor its Regulation Services Provider (as that term is defined in the policies of the Toronto Stock Exchange) accepts responsibility for the adequacy or accuracy of this release.
Contact Information
Company Contact:
William V. Williams, MD
President & CEO
1-888-485-6340
info@briacell.com
Media Relations:
Jules Abraham
CORE IR
julesa@coreir.com
Investor Relations Contact:
CORE IR
investors@briacell.com
FAQ
When will BriaCell (BCTX) present at the 2024 San Antonio Breast Cancer Symposium?
What will BriaCell (BCTX) present at SABCS 2024?
What is the focus of BriaCell's (BCTX) Phase 3 study expansion?
